Sharyn I Katz

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Radiation dose associated with unenhanced CT for suspected renal colic: impact of repetitive studies
    Sharyn I Katz
    Department of Radiology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT 06520 8042, USA
    AJR Am J Roentgenol 186:1120-4. 2006
  2. ncbi FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy
    Sharyn I Katz
    Department of Radiology, University of Pennsylvania School of Medicine, 1 Silverstein Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Int J Oncol 39:91-100. 2011
  3. ncbi A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma
    Daniel H Sterman
    Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, 19104 4283, USA
    Am J Respir Crit Care Med 184:1395-9. 2011
  4. ncbi Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma
    Sharyn I Katz
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer Biol Ther 8:2406-16. 2009
  5. ncbi A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions
    Daniel H Sterman
    Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Mol Ther 18:852-60. 2010

Detail Information

Publications5

  1. ncbi Radiation dose associated with unenhanced CT for suspected renal colic: impact of repetitive studies
    Sharyn I Katz
    Department of Radiology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT 06520 8042, USA
    AJR Am J Roentgenol 186:1120-4. 2006
    ....
  2. ncbi FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy
    Sharyn I Katz
    Department of Radiology, University of Pennsylvania School of Medicine, 1 Silverstein Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Int J Oncol 39:91-100. 2011
    ..Thus, tumor imaging response by FLT may be limited in human tumors without functional p53...
  3. ncbi A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma
    Daniel H Sterman
    Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, 19104 4283, USA
    Am J Respir Crit Care Med 184:1395-9. 2011
    ..Clinical trial registered with www.clinicaltrials.gov (NCT 01212367)...
  4. ncbi Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma
    Sharyn I Katz
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer Biol Ther 8:2406-16. 2009
    ..We document single agent activity of sorafenib against MPM, unravel novel effects of sorafenib on anti-apoptotic signaling mediators, and suggest the combination of sorafenib plus TRAIL as possible therapy for clinical testing in MPM...
  5. ncbi A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions
    Daniel H Sterman
    Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Mol Ther 18:852-60. 2010
    ..This approach was safe, induced immune responses and disease stability. However, rapid development of Nabs prevented effective gene transfer after the second dose, even with a dose interval as short as 7 days...